Cancer Stem Cells: A New Approach to Treating Cancer

Cancer stem cells are a hot, promising new approach to treating cancer--one which may not only prevent cancer from spreading, but also help diagnose and even cure the disease. Start-ups are beginning to emerge, and so is investor interest.

Cancer stem cells are fast emerging as a promising new approach to treating cancer—one that may not only prevent cancer from spreading but also may help diagnose and even cure the disease. The concept of cancer stem cells has been around for several decades, but only in the last 10 years or so have studies appeared that prove their existence in a variety of cancer types. The term refers to a small number of cells in a tumor or blood cancer shown to be capable of seeding new tumors and causing the cancer to proliferate---just as regular stem cells reproduce and can differentiate into a variety of normal tissue types.

First uncovered in leukemia in the late '90s, cancer stem cells have since been identified in a range of solid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

More from Business

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.